secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0000950170-23-041949
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar Life Sciences delays KZR-261 dose expansion to 2024, still enrolling Cohort 7
--------------------------------------------------------------------------------

- Phase 1 trial of KZR-261 in solid tumors enrolling Cohort 7 (40 mg/m2); no MTD reached yet.
- Revised forecast pushes safety/dose escalation data report and dose expansion start to 2024.
- Topline data from expansion portion to be reported when available.
- Trial evaluates safety, PK/PD, and preliminary anti-tumor activity in locally advanced/metastatic disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000095017023041949/0000950170-23-041949-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000095017023041949/kzr-20230811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041949

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer